Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
A comprehensive single-cell analysis of clear cell renal cell carcinoma reveals a previously uncharacterized tip-cell like endothelial phenotype and uncovers immunosuppressive clinically relevant targetable interactions in the tumor microenvironment.
HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.
"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
In a randomized phase 1 trial, the addition of a live Clostridium species-containing product to a tyrosine kinase inhibitor and anti-programmed cell death protein 1 treatment combination did not increase bacterial abundance of Bifidobacterium spp. but enhanced clinical responses in ...
Dr Katy Beckermann introduces the panel of experts and addresses the first clinical case in this series, highlighting intermediate-risk, metastatic clear cell renal cell carcinoma.
During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.
Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma (RCC). The conversation emphasizes the landmark approval of pembrolizumab as adjuvant therapy in early-stage RCC, highlighting a ...
... clear cell renal cell carcinoma (ccRCC). The rolling BLA submission, initiated in December 2023 with timelines pre-agreed with the FDA, was ...
Key opinion leaders explore renal cell carcinoma subtypes, their incidence rates, primary sites of origin, and frequently observed genetic mutations.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.